Inflammatory diseases sales will grow through 2036, led by asthma at 20.3% of the diseases segment in 2026, driven by expanding clinical protocols and institutional procurement requirements. The market was valued at USD 22.5 billion in 2025 and is expected to be worth USD 36.51 billion by 2036.